$RLFTF (related) DD by Serge on Yh0 - Just for inf
Post# of 653
(Total Views: 363)
Posted On: 05/21/2021 5:22:12 PM
$RLFTF (related) DD by Serge on Yh0 - Just for information, for all new boardmembers. Aviptadil is not only targetting Covid 19
VIP is shown to have important potential effects in the treatment of other lung diseases including Chronic Obstructive Pulmonary Disease
(“COPD”), Sarcoidosis, asthma/allergy, and Chronic Respiratory Inflammation Syndrome.
NeuroRx intends to research the use of VIP in these and other conditions in the future.
VIP is also known to be active in the brain and NeuroRx plans to
explore its potential use in the treatment of Huntington’s Disease, Multiple Sclerosis, and other CNS diseases if an
appropriate mechanism of CNS delivery can be developed
DD on VIP by changes v - To develop potential therapies for Parkinson’s disease, inflammatory processes, mitochondrial dynamics, oxidative stress, production of reactive aldehydes, excitotoxicity and synucleinopathies are to be targeted.
In this respect, vasoactive intestinal peptide has beneficial effects that provide an advantage for the treatment of Parkinson’s disease. Vasoactive intestinal peptide is a major neuropeptide-neurotransmitter having antioxidant, anti-inflammatory, neurotropic, neuromodulator, and anti-apoptotic properties.
In addition to its direct neuroprotective actions regulating the activity of astrocytes, microglia and brain mast cells, it also plays important roles for neuronal adaptation, maintenance and survival.
https://www.eurekaselect.com/168911/article
The Parkinson's disease treatment market was valued at USD 3.99 billion in 2016 and expected to grow at a CAGR of 6.1% from 2017 to 2022 to reach USD 5.69 billion in 2022. The carbidopa/levodopa drug class is projected to register highest CAGR during forecast period.
https://www.marketsandmarkets.com/Market-Repo...65247.html
VIP is shown to have important potential effects in the treatment of other lung diseases including Chronic Obstructive Pulmonary Disease
(“COPD”), Sarcoidosis, asthma/allergy, and Chronic Respiratory Inflammation Syndrome.
NeuroRx intends to research the use of VIP in these and other conditions in the future.
VIP is also known to be active in the brain and NeuroRx plans to
explore its potential use in the treatment of Huntington’s Disease, Multiple Sclerosis, and other CNS diseases if an
appropriate mechanism of CNS delivery can be developed
DD on VIP by changes v - To develop potential therapies for Parkinson’s disease, inflammatory processes, mitochondrial dynamics, oxidative stress, production of reactive aldehydes, excitotoxicity and synucleinopathies are to be targeted.
In this respect, vasoactive intestinal peptide has beneficial effects that provide an advantage for the treatment of Parkinson’s disease. Vasoactive intestinal peptide is a major neuropeptide-neurotransmitter having antioxidant, anti-inflammatory, neurotropic, neuromodulator, and anti-apoptotic properties.
In addition to its direct neuroprotective actions regulating the activity of astrocytes, microglia and brain mast cells, it also plays important roles for neuronal adaptation, maintenance and survival.
https://www.eurekaselect.com/168911/article
The Parkinson's disease treatment market was valued at USD 3.99 billion in 2016 and expected to grow at a CAGR of 6.1% from 2017 to 2022 to reach USD 5.69 billion in 2022. The carbidopa/levodopa drug class is projected to register highest CAGR during forecast period.
https://www.marketsandmarkets.com/Market-Repo...65247.html
(0)
(0)Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ